Refine
Has Fulltext
- yes (831) (remove)
Year of publication
- 2012 (831) (remove)
Document Type
- Journal article (373)
- Doctoral Thesis (373)
- Complete part of issue (48)
- Preprint (8)
- Report (8)
- Book (4)
- Book article / Book chapter (4)
- Jahresbericht (3)
- Review (3)
- Conference Proceeding (2)
Keywords
- Würzburg (50)
- Universität (46)
- Wuerzburg (44)
- Wurzburg (44)
- Medizin (43)
- University (42)
- hadron-hadron scattering (15)
- Biologie (13)
- Psychologie (12)
- melanoma (10)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (94)
- Universität Würzburg (47)
- Graduate School of Life Sciences (43)
- Fakultät für Physik und Astronomie (39)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (28)
- Medizinische Klinik und Poliklinik I (28)
- Institut für Psychologie (27)
- Physikalisches Institut (27)
- Neurologische Klinik und Poliklinik (25)
- Institut für Molekulare Infektionsbiologie (24)
Sonstige beteiligte Institutionen
Introduction. To assess the role of adjuvant androgen deprivation therapy (ADT) in high-risk prostate cancer patients (PCa) after surgery. Materials and Methods. The analysis case matched 172 high-risk PCa patients with positive section margins or non-organ confined disease and negative lymph nodes to receive adjuvant ADT (group 1, n=86 ) or no adjuvant ADT (group 2, n=86). Results. Only 11.6% of the patients died, 2.3% PCa related. Estimated 5–10-year clinical progression-free survival was 96.9% (94.3%) for group 1 and 73.7% (67.0%) for group 2, respectively. Subgroup analysis identified men with T2/T3a tumors at low-risk and T3b margins positive disease at higher risk for progression. Conclusion. Patients with T2/T3a tumors are at low-risk for metastatic disease and cancer-related death and do not need adjuvant ADT. We identified men with T3b margin positive disease at highest risk for clinical progression. These patients benefit from immediate adjuvant ADT.